Article thumbnail

Antiviral Inhibition of Enveloped Virus Release by Tetherin/BST-2: Action and Counteraction

By Anna Le Tortorec, Suzanne Willey and Stuart J. D. Neil

Abstract

Tetherin (BST2/CD317) has been recently recognized as a potent interferon-induced antiviral molecule that inhibits the release of diverse mammalian enveloped virus particles from infected cells. By targeting an immutable structure common to all these viruses, the virion membrane, evasion of this antiviral mechanism has necessitated the development of specific countermeasures that directly inhibit tetherin activity. Here we review our current understanding of the molecular basis of tetherin’s mode of action, the viral countermeasures that antagonize it, and how virus/tetherin interactions may affect viral transmission and pathogenicity

Topics: Review
Publisher: Molecular Diversity Preservation International (MDPI)
OAI identifier: oai:pubmedcentral.nih.gov:3185764
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2009). A cd317/tetherin-rich2 complex plays a critical role in the organization of the subapical actin cytoskeleton in polarized epithelial cells.
  2. (1997). A full-length and replication-competent proviral clone of sivagm from tantalus monkeys. Virology
  3. (1998). A novel human wd protein, h-beta trcp, that interacts with hiv-1 vpu connects cd4 to the er degradation pathway through an f-box motif.
  4. (2000). An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus.
  5. (2007). An interferon-alpha-induced tethering mechanism inhibits hiv-1 and ebola virus particle release but is counteracted by the hiv-1 vpu protein. Cell Host Microbe
  6. (2010). Ancient adaptive evolution of tetherin shaped the functions of vpu and nef in human immunodeficiency virus and primate
  7. Antagonism of cd317 restriction of human immunodeficiency virus type 1 (hiv-1) particle release and depletion of cd317 are separable activities of hiv-1 vpu.
  8. (2010). Antagonism of tetherin restriction of hiv-1 release by vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog.
  9. (2009). Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope
  10. (2010). Anti-tetherin activities in vpu-expressing primate lentiviruses. Retrovirology
  11. (1999). Ataxia in prion protein (prp)-deficient mice is associated with upregulation of the novel prp-like protein
  12. (1995). Augmentation of virus secretion by the human immunodeficiency virus type 1 vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes.
  13. (2008). Avoiding the void: Cell-to-cell spread of human viruses.
  14. Biofilm-like extracellular viral assemblies mediate htlv-1 cell-tocell transmission at virological synapses.
  15. (2011). Bone marrow stromal cell antigen 2 is a specific marker of type i ifn-producing cells in the naive mouse, but a promiscuous cell surface antigen following ifn stimulation.
  16. (2009). Broad-spectrum inhibition of retroviral and filoviral particle release by
  17. (2011). Bst-2 is rapidly down-regulated from the cell surface by the hiv-1 protein vpu: Evidence for a post-er mechanism of vpu-action. Virology
  18. (2003). Bst-2/hm1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic
  19. Cd317/tetherin is enriched in the hiv-1 envelope and downregulated from the plasma membrane upon virus infection.
  20. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/bst-2-mediated restriction in t cells.
  21. (2007). Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif.
  22. (2011). Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/bst-2 in a pathogenic nef-deleted siv. Cell Host Microbe
  23. (2003). Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys.
  24. (2010). Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 vpu
  25. Differential effects of human immunodeficiency virus type 1 vpu on the stability of bst-2/tetherin.
  26. (2010). Direct restriction of virus release and incorporation of the interferon-induced protein bst-2 into hiv-1 particles. PLoS Pathog.
  27. (2010). Ebola virus glycoprotein counteracts bst-2/tetherin restriction in a sequence-independent manner that does not require tetherin surface
  28. (2010). Endogenous cd317/tetherin limits replication of hiv-1 and murine leukemia virus in rodent cells and is resistant to antagonists from primate viruses.
  29. (2005). Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production.
  30. (1989). Functional role of human immunodeficiency virus type 1 vpu.
  31. (2009). Hiv-1 accessory protein vpu internalizes cell-surface bst-2/tetherin through transmembrane interactions leading to lysosomes.
  32. (2009). Hiv-1 antagonism of cd317 is species specific and involves vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe
  33. (2007). Hiv-1 buds predominantly at the plasma membrane of primary human macrophages. PLoS Pathog.
  34. (2010). Hiv-1 vpu and hiv-2 env counteract bst-2/tetherin by sequestration in a perinuclear compartment. Retrovirology
  35. (2009). Hiv-1 vpu neutralizes the antiviral factor tetherin/bst-2 by binding it and directing its beta-trcp2-dependent degradation. PLoS Pathog.
  36. (2006). Hiv-1 vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog.
  37. (2009). Hm1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin.
  38. (2009). Human immunodeficiency virus, restriction factors, and interferon.
  39. (2011). Identification of amino acids in the human tetherin transmembrane domain responsible for hiv-1 vpu interaction and
  40. (2011). Ifn-gamma-induced bst2 mediates monocyte adhesion to human endothelial cells. Cell Immunol.
  41. (2010). Immunoelectron microscopic evidence for tetherin/bst2 as the physical bridge between hiv-1 virions and the plasma membrane. PLoS Pathog.
  42. (1997). Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, hm1.24. Blood
  43. (2007). In macrophages, hiv-1 assembles into an intracellular plasma membrane domain containing the tetraspanins cd81, cd9, and cd53.
  44. (2010). Infectious lassa virus, but not filoviruses, is restricted by bst-2/tetherin.
  45. (2009). Inhibition of lassa and marburg virus production by
  46. Interferon-induced cell membrane proteins, ifitm3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms.
  47. (2010). Interplay between ovine bone marrow stromal cell antigen 2/tetherin and endogenous
  48. (1999). Lack of effect of cytoplasmic tail truncations on human immunodeficiency virus type 2 rod env particle release
  49. (2003). Large-scale identification and characterization of human genes that activate nf-kappab and mapk signaling pathways. Oncogene
  50. (2009). Lipids and membrane microdomains in hiv-1 replication. Virus Res.
  51. (2010). Modulation of hiv-1-host interaction: Role of the vpu accessory protein. Retrovirology
  52. (1989). Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu
  53. (2009). Molecular mechanism of bst2/tetherin downregulation by k5/mir2 of kaposi's sarcoma-associated
  54. (2009). Mutation of a single residue renders human tetherin resistant to hiv-1 vpu-mediated depletion. PLoS Pathog.
  55. (2003). Naturally occurring amino acid substitutions in the hiv-2 rod envelope glycoprotein regulate its ability to augment viral particle release. Virology
  56. (2009). Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe
  57. (2006). Plasma membrane is the site of productive hiv-1 particle assembly. PLoS Biol.
  58. (2006). Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog.
  59. (2006). Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release.
  60. (2009). Regulation of tlr7/9 responses in plasmacytoid dendritic cells by bst2 and ilt7 receptor interaction.
  61. (1999). Regulation of virus release by the macrophagetropic human immunodeficiency virus type 1 ad8 isolate is redundant and can be controlled by either vpu or
  62. (2011). Serine-threonine ubiquitination mediates downregulation of bst-2/tetherin and relief of restricted virion release by hiv-1 vpu.
  63. (2007). Silencing of both beta-trcp1 and hos (beta-trcp2) is required to suppress human immunodeficiency virus type 1 vpu-mediated cd4 down-modulation.
  64. (2009). Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/bst-2/cd317 by intracellular sequestration.
  65. (2009). Species-specific activity of hiv-1 vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog.
  66. (2009). Species-specific activity of siv nef and hiv-1 vpu in overcoming restriction by tetherin/bst2. PLoS Pathog.
  67. (2011). Structural and biophysical analysis of bst-2/tetherin ectodomains reveals an evolutionary conserved design to inhibit virus release.
  68. (2010). Structural and functional studies on the extracellular domain of bst2/tetherin in reduced and oxidized conformations.
  69. (2010). Structural basis of hiv-1 tethering to membranes by the bst-2/tetherin ectodomain. Cell Host Microbe
  70. (2010). Structural insight into the mechanisms of enveloped virus tethering by tetherin.
  71. (2009). Suppression of tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of vpu in the trans-golgi
  72. (2010). Susceptibility of xenotropic murine leukemia virus-related virus (xmrv) to retroviral restriction factors.
  73. (2009). Tetherin inhibits hiv-1 release by directly tethering virions to cells. Cell
  74. (2008). Tetherin inhibits retrovirus release and is antagonized by hiv-1 vpu.
  75. (2010). Tetherin restricts direct cell-to-cell infection of hiv-1. Retrovirology
  76. (2010). Tetherin restricts productive hiv-1 cell-to-cell transmission. PLoS Pathog.
  77. (2009). Tetherin-driven adaptation of vpu and nef function and the evolution of pandemic and nonpandemic hiv-1 strains. Cell Host Microbe
  78. (2009). Tetherin-mediated restriction of filovirus budding is antagonized by the ebola glycoprotein.
  79. (1993). The effect of vpu on hiv-1-induced syncytia formation.
  80. (1996). The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: A vpu-like factor?
  81. (2011). The escrt-0 component hrs is required for hiv-1 vpu-mediated bst-2/tetherin down-regulation. PLoS Pathog.
  82. (2009). The formation of cysteine-linked dimers of bst-2/tetherin is important for inhibition of hiv-1 virus release but not for sensitivity to vpu. Retrovirology
  83. (2010). The great escape: Viral strategies to counter bst-2/tetherin. PLoS Pathog.
  84. (1996). The human immunodeficiency virus (hiv) type 2 envelope protein is a functional complement to hiv type 1 vpu that enhances particle release of heterologous retroviruses.
  85. (1990). The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and
  86. (1999). The humanized anti-hm1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity.
  87. (2008). The interferon-induced protein bst-2 restricts hiv-1 release and is downregulated from the cell surface by the viral vpu protein. Cell Host Microbe
  88. (1999). The nature of the principal type 1 interferon-producing cells in human blood. Science
  89. (2006). The pericentriolar recycling endosome plays a key role in vpu-mediated enhancement of hiv-1 particle release. Traffic
  90. (2010). The ring-ch ligase k5 antagonizes restriction of kshv and hiv-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog.
  91. (2009). The trafficking and regulation of membrane receptors by the ring-ch ubiquitin e3 ligases. Exp. Cell Res.
  92. (2009). The transmembrane domain of bst-2 determines its sensitivity to downmodulation by human immunodeficiency virus type 1
  93. (2010). Virus cell-to-cell transmission.
  94. (2009). Vpu antagonizes bst-2-mediated restriction of hiv-1 release via beta-trcp and endo-lysosomal trafficking. PLoS Pathog.
  95. (2009). Vpu directs the degradation of the human immunodeficiency Virus Res.triction factor bst-2/tetherin via a {beta}trcp-dependent
  96. (2009). Vpu enhances hiv-1 virus release in the absence of bst-2 cell surface down-modulation and intracellular depletion.
  97. (1993). Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses.
  98. (2010). Vpu serine 52 dependent counteraction of tetherin is required for hiv-1 replication in macrophages, but not in ex vivo human lymphoid tissue. Retrovirology